MXCT MaxCyte, Inc.

NASDAQ
$1.32

MaxCyte, Inc. (MXCT) is expected to report earnings on November 11, 2026, after the market close. The consensus earnings estimate is a loss of $0.08 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +12.8% since its last earnings release on August 12, 2026.

MaxCyte Beat Consensus Estimates, Reaffirms
Wednesday, August 12, 2026 · 4:05 PM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 11
Wednesday · 4:05 PM ET
Earnings Whisper
-
vs ($0.08)
Rev est $7M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $1.38

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About MaxCyte, Inc.

MaxCyte is a leading provider of cell-engineering platform technologies to advance innovative cell-based research, development and potential commercialization of next-generation cell therapies.

Sector

Healthcare

Industry

Medical Instruments/Supply

Held By 1 ETFs, by dollar flow